193 related articles for article (PubMed ID: 28450199)
1. Severe glandular tularemia in a patient treated with anti-tumour necrosis factor for psoriatic arthritis.
Calin R; Caumes E; Reibel F; Ali Mohamed A; Brossier F; Foltz V; Boussouar S; Fautrel B; Maurin M; Katlama C; Pourcher V
Int J Infect Dis; 2017 Jul; 60():1-3. PubMed ID: 28450199
[TBL] [Abstract][Full Text] [Related]
2. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour necrosis factor-induced cutaneous leishmaniasis in patient with psoriatic arthritis and uveitis.
Hernandez Bel L; Hernández Garfella ML; Chiarri Toumit C; Valenzuela Oñate C
Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):621-622. PubMed ID: 30100239
[No Abstract] [Full Text] [Related]
4. Psoriatic arthritis.
Durham LE; Taams LS; Kirkham BW
Br J Hosp Med (Lond); 2016 Jul; 77(7):C102-8. PubMed ID: 27388392
[No Abstract] [Full Text] [Related]
5. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
6. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
7. Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.
Soubrier M; Pereira B; Frayssac T; Abdi D; Couderc M; Daron C; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Clin Exp Rheumatol; 2016; 34(6):1059-1064. PubMed ID: 27607233
[TBL] [Abstract][Full Text] [Related]
8. Alopecia areata universalis elicited during treatment with adalimumab.
Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
[TBL] [Abstract][Full Text] [Related]
9. [Severe tularaemia mimicking glandular tuberculosis during adalimumab therapy].
Konstantinou MP; Abecassis-Cotta S; Valeyrie-Allanore L; Ortonne N; Maurin M; Roujeau JC; Revuz J; Bagot M
Ann Dermatol Venereol; 2009 Oct; 136(10):718-22. PubMed ID: 19801257
[TBL] [Abstract][Full Text] [Related]
10. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab.
Borrás-Blasco J; Gracia-Perez A; Nuñez-Cornejo C; Rosique-Robles JD; Mateu-Puchades A; Casterá MD; Rubio-Fabra M
J Clin Pharm Ther; 2008 Jun; 33(3):321-5. PubMed ID: 18452420
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
Eder L; Thavaneswaran A; Chandran V; Gladman DD
Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
13. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.
Lories RJ; de Vlam K
Expert Opin Biol Ther; 2014 Dec; 14(12):1825-36. PubMed ID: 25366335
[TBL] [Abstract][Full Text] [Related]
15. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
Gniadecki R; Bang B; Sand C
Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
[No Abstract] [Full Text] [Related]
16. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-α and risk of infections: the experience in one center.
Maruotti N; D'Onofrio F; Neve A; Santoro N; Corrado A; Cantatore FP
Panminerva Med; 2014 Mar; 56(1):31-4. PubMed ID: 24637471
[TBL] [Abstract][Full Text] [Related]
18. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kalstad S; Rødevand E; Mikkelsen K; Lexberg AS; Kvien TK
Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
[TBL] [Abstract][Full Text] [Related]
19. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of action of biological disease--modifying antirheumatic drugs].
Takahashi N; Ishiguro N
Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
